AstraZeneca : Very good start to the year
>Q1 better than expected, $ 275m in COVID-19 sales in Q1 - AZN reported better than expected Q1 results (+5.5% vs the consensus for revenues, +10% vs the consensus for EPS).Growth at constant currencies came to +11% for sales and +55% for earnings. The operating margin improved by 5 percentage points. The first COVID-19 vaccine sales amounted to $ 275m in the quarter.Guidance maintained... for the time being in our view - AstraZeneca reiterated i...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.